Minireviews
Copyright ©The Author(s) 2022.
World J Gastroenterol. Nov 14, 2022; 28(42): 6034-6044
Published online Nov 14, 2022. doi: 10.3748/wjg.v28.i42.6034
Table 1 Currently approved anti-angiogenic therapy for advanced hepatocellular carcinoma
Therapy
Type
Line of therapy
Target
Study name
Primary outcome in the study (mo) (95%CI)
Adverse events in the study [affected/at risk (%)]
Anti-VEGFA
Bevacizumab (combination with atezolizumab)mAbFirst line (plus atezolizumab)VEGF-AIMBrave150OS at CCOD 30 mo: 19.2 (17.0-23.7); PFS: 6.8 (5.6-8.3)Gastrointestinal perforation [1/329 (0.30%)], haemorrhage [40/329 (12.15%)], hypertension [2/329 (0.61%)] and proteinuria [100/329 (30.40%)], etc.
Anti-VEGFR
SorafenibTKIsFirst lineVEGFR1-3, c-Kit, PDGFR-b, and FLT-3SHARPOS: 10.8 (9.5-13.5); TTSP: 4.2 (3.5-4.2)Diarrhea [166/297 (55.89%)], hand-foot skin reactions [2/297 (0.67%)], fatigue [145/297 (48.82%)], etc.
LenvatinibTKIsFirst lineVEGFR1-3, FGFR1-4, PDGFRa, RET and c-KitREFLECTOS: 13.6 (12.1–14.9); PFS: 7.4 (6.9–8.8)Diarrhea [154/468 (33%)], decreased appetite [204/468 (44%)], etc.
RegorafenibTKIsSecond lineVEGFR, RET, c-Kit, B-Raf, FGFR1 and PDGFRRESORCEOS: 10.7 (9.2-12.3); TTP:3.9 (2.9-4.26)Toxicities were manageable this sorafenib- tolerant population and were similar to those observed with sorafenib, including diarrhea [163/374 (43.58%)], etc.
CabozantinibTKIsSecond and third lineVEGFR2, c-Kit, RET, FLT-3, Tie2, and AxlCELESTIALOS: 10.2 (9.1-12.0)Hypertension [137/467 (29.34%)]. Pneumonia [16/467 (3.43%)], etc.
RamucirumabmAbSecond line and AFP ≥ 400 ng/mLVEGFR2REACH-2OS: 8.5 (7.0-10.6)Hypertension [48/197 (24.37%)], hyponatremia [11/197 (5.58%)], etc.